Evidence map›Paper›PMID 40862729›Full record

ArticleCells2025

DIRAS3 Inhibits Ovarian Cancer Cell Growth by Blocking the Fibronectin-Mediated Integrin β1/FAK/AKT Signaling Pathway.

Jing Guo, Janice M Santiago-O'Farrill, Vivian Orellana, Rumeysa Ozyurt, Hailing Yang, Marc Pina, Gamze Bildik, Weiqun Mao, Robert C Bast, Zhen Lu

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing GuoDepartment of Obstetrics and Gynecology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Janice M Santiago-O'FarrillDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-7714-7962
Vivian OrellanaDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Rumeysa OzyurtDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Hailing YangDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Marc PinaDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Gamze BildikDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-7596-2381
Weiqun MaoDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Robert C BastDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0003-4621-8462
Zhen LuDepartment of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.ORCID 0000-0002-9596-0148

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
The University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROBERT C BAST, ANIL K SOOD · 2023 to 2026
$11.5M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9M
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibitionR01CA266187 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, LU, ZHEN · 2022 to 2025
$2.9M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA217685NCI NIH HHS P50 CA281701NCI NIH HHS R01 CA266187
6 · The paper itself

Abstract

Autophagy is a crucial cellular process responsible for sustaining homeostasis through the degradation and recycling of proteins and organelles, providing energy during amino acid starvation and hypoxia. In cancer, autophagy can either inhibit tumor growth or support cancer cell survival. Our previous studies have shown that re-expression of the tumor suppressor gene

Indexed as

FibronectinsFocal Adhesion Kinase 1Integrin beta1Ovarian NeoplasmsProto-Oncogene Proteins c-aktSignal TransductionAnimalsAutophagyCell Line, TumorCell ProliferationFemaleHumansMiceMice, NudeFibronectinsFocal Adhesion Kinase 1Integrin beta1Proto-Oncogene Proteins c-aktPTK2 protein, humanautophagyFAKfibronectinintegrinovarian cancer

Identifiers

PMID40862729
PMCPMC12384585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.